SAN

102.6

+0.02%↑

EI

267.1

-0.04%↓

SHL.DE

49.84

-0.91%↓

ARGX

545

+0.52%↑

FRE

39.53

+0.51%↑

SAN

102.6

+0.02%↑

EI

267.1

-0.04%↓

SHL.DE

49.84

-0.91%↓

ARGX

545

+0.52%↑

FRE

39.53

+0.51%↑

SAN

102.6

+0.02%↑

EI

267.1

-0.04%↓

SHL.DE

49.84

-0.91%↓

ARGX

545

+0.52%↑

FRE

39.53

+0.51%↑

SAN

102.6

+0.02%↑

EI

267.1

-0.04%↓

SHL.DE

49.84

-0.91%↓

ARGX

545

+0.52%↑

FRE

39.53

+0.51%↑

SAN

102.6

+0.02%↑

EI

267.1

-0.04%↓

SHL.DE

49.84

-0.91%↓

ARGX

545

+0.52%↑

FRE

39.53

+0.51%↑

Search

UCB SA

Abierto

SectorSalud

163.95 -0.06

Resumen

Variación precio

24h

Actual

Mínimo

160.45

Máximo

165.7

Métricas clave

By Trading Economics

Ingresos

208M

Ventas

2.8B

P/B

Media del Sector

32.687

73.239

BPA

2.09

Rentabilidad por dividendo

0.76

Margen de beneficio

7.453

Empleados

9,052

EBITDA

644M

Recomendaciones

By TipRanks

Recomendaciones

Comprar

Estimación a 12 meses

+19.23% upside

Dividendos

By Dow Jones

Rentabilidad por dividendo

Media del Sector

0.76%

3.06%

Estadísticas de Mercado

By TradingEconomics

Capitalización de Mercado

-1.4B

34B

Apertura anterior

164.01

Cierre anterior

163.95

Noticias sobre sentimiento de mercado

By Acuity

46%

54%

152 / 386 Clasificación en Healthcare

UCB SA Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

31 mar 2025, 22:45 UTC

Principales Noticias

Intel's New CEO Plots Turnaround; 'We Need to Improve'

31 mar 2025, 23:54 UTC

Charlas de Mercado

Nikkei May Rise After Monday's Selloff -- Market Talk

31 mar 2025, 23:44 UTC

Charlas de Mercado

Gold Edges Higher Amid Prospects of Broader, Higher U.S. Tariffs -- Market Talk

31 mar 2025, 23:15 UTC

Charlas de Mercado

Tower Shares Ease After Bain Capital Exit -- Market Talk

31 mar 2025, 23:15 UTC

Charlas de Mercado

Global Equities Roundup: Market Talk

31 mar 2025, 22:33 UTC

Principales Noticias

Trump Administration Targets Harvard With Review of $9 Billion in Federal Funding -- Update

31 mar 2025, 22:28 UTC

Ganancias

China Vanke: Weak China Real-Estate Market Weighed on Results >000002.SZ

31 mar 2025, 22:28 UTC

Ganancias

China Vanke 2024 Loss CNY49.48B Vs. Net CNY12.16B >000002.SZ

31 mar 2025, 22:28 UTC

Ganancias

China Vanke 2024 Rev CNY343.18B Vs. CNY465.74B >000002.SZ

31 mar 2025, 22:28 UTC

Ganancias

China Vanke Swings to Loss for 2024 >000002.SZ

31 mar 2025, 21:47 UTC

Principales Noticias

Intel's New CEO Says Turnaround 'Won't Be Easy' -- Barrons.com

31 mar 2025, 21:44 UTC

Principales Noticias

Trump Administration Targets Harvard With Review of $9 Billion in Federal Funding -- WSJ

31 mar 2025, 21:21 UTC

Charlas de Mercado

Intel Has 'A Lot of Hard Work Ahead' in Turnaround, CEO Says -- Market Talk

31 mar 2025, 21:18 UTC

Principales Noticias

Copper Is 2025's Hottest Commodity -- Update

31 mar 2025, 21:09 UTC

Principales Noticias

Senate Aims to Advance Trump Tax Agenda While Postponing Spending-Cut Fight -- Update

31 mar 2025, 21:02 UTC

Ganancias

Freeport-McMoRan Sees 1Q Gold Sales 100,000 Ounces Below Previous Guidance of 225,000 Ounces >FCX

31 mar 2025, 21:01 UTC

Ganancias

Freeport-McMoRan Backs 1Q Consolidated Copper Sales of 850M Pounds >FCX

31 mar 2025, 20:50 UTC

Charlas de Mercado

Financial Services Roundup: Market Talk

31 mar 2025, 20:50 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

31 mar 2025, 20:37 UTC

Principales Noticias

A Wild Quarter for U.S. Stocks Sends Investors Abroad -- 3rd Update

31 mar 2025, 20:17 UTC

Principales Noticias

Dow Bounced Back After Tariff Concerns Hit Global Markets -- WSJ

31 mar 2025, 20:13 UTC

Principales Noticias

A Wild Quarter for U.S. Stocks Sends Investors Abroad -- 2nd Update

31 mar 2025, 20:03 UTC

Principales Noticias

A Wild Quarter for U.S. Stocks Sends Investors Abroad -- Update

31 mar 2025, 19:09 UTC

Charlas de Mercado

Oil At 5-Week High as Trump Makes More Sanction Threats -- Market Talk

31 mar 2025, 18:56 UTC

Charlas de Mercado

U.S. Natural Gas Gains With Help From Weather -- Market Talk

31 mar 2025, 18:54 UTC

Charlas de Mercado

Canadian Banks' Fundamentals to Support Credit Ratings Near Term -- Market Talk

31 mar 2025, 18:40 UTC

Charlas de Mercado

Walmart's Low Income Consumer Appears Increasingly Strained -- Market Talk

31 mar 2025, 18:34 UTC

Charlas de Mercado

Ball, Crown Won't Be Materially Hurt if Soda Kicked Off Food Stamps -- Market Talk

31 mar 2025, 18:28 UTC

Charlas de Mercado

Gold Climbs to Close Out Quarter -- Market Talk

31 mar 2025, 18:03 UTC

Principales Noticias

Dow Edges Higher, Tariff Concerns Drag Down Global Markets -- WSJ

Comparación entre iguales

Cambio de precio

UCB SA Esperado

Precio Objetivo

By TipRanks

19.23% repunte

Estimación a 12 meses

Media 94.86 EUR  19.23%

Máximo 125 EUR

Mínimo 74 EUR

De acuerdo con 7 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para UCB SA Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

7 ratings

4

Comprar

1

Mantener

2

Vender

Sentimiento

By Acuity

152 / 386 Clasificación en Salud

Noticias sobre sentimiento de mercado

Coyuntura alcista

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por debajo de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de UCB SA

UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies. It also offers Evenity for the treatment of osteoporosis in postmenopausal women; Bimzelx for treating plaque psoriasis, psoriatic arthritis, and axial spondyloarthritis; and Fintepla to treat Dravet syndrome. In addition, the company is involved in developing rozanolixizumab and Zilbrisq to treat myasthenia gravis; dapirolizumab pegol for systemic lupus erythematosus; fenfluramine to treat CDKL5 deficiency disorder; doxecitine for TK2 deficiency disorder; STACCATO alprazolam for stereotypical prolonged seizures; bepranemab to treat Alzheimer's disease; minzasolmin and UCB0222 for Parkinson's disease; and UCB1381 and UCB9741 for atropic dermatitis. Further, it engages in contract manufacturing activities. UCB SA has collaboration agreements with Amgen, Biogen, Roche/Genentech, Novartis, and Otsuka. The company was incorporated in 1925 and is headquartered in Brussels, Belgium.